Analytical Data
-
Gene name
Erythropoietin/EPO
- Application
-
Alternative Names
rHuEPO; Epoetin; EPO
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01588
-
Expression Region
A28-R193
-
Protein Length
Full Length of Mature Protein
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Erythropoietin (EPO) is a glycoprotein hormone primarily produced in the kidneys that stimulates erythropoiesis, the production of red blood cells. Its significant role in regulating erythrocyte formation makes it a critical factor in managing conditions associated with anemia, particularly in patients with chronic kidney disease, cancer, and those undergoing chemotherapy. The recombinant form of EPO, known as recombinant human erythropoietin (rHuEPO), was developed in the late 20th century through recombinant DNA technology and has transformed therapeutic approaches in hematology. Research on rHuEPO has expanded beyond its primary indication for anemia, investigating its potential neuroprotective effects in various neurological conditions and its application in enhancing exercise performance, albeit with ethical implications in sports. Furthermore, ongoing studies focus on optimizing the pharmacokinetics, efficacy, and safety profile of different EPO formulations, including pegylated versions which provide longer-lasting effects. The development of biosimilars also reflects the growing interest and market potential for EPO variants. Overall, the extensive research into EPO and its recombinant forms has underscored their importance in both clinical practice and biomedical research, highlighting the evolving landscape of therapeutic interventions targeting erythropoiesis.
